Twitter | Search | |
Pharmaxis
A pharmaceutical research company with approved products in world markets and a drug discovery program focused on treatments for fibrosis and inflammation.
147
Tweets
147
Following
183
Followers
Tweets
Pharmaxis Feb 24
Pharmaxis sees progress in Boehringer Ingelheim’s clinical trial in patients with NASH via
Reply Retweet Like
Pharmaxis Feb 21
First subject dosed in the Pharmaxis phase 1 clinical trial of a drug discovery to treat severe fibrosis and cancer.
Reply Retweet Like
Pharmaxis retweeted
Stockhead Feb 21
Fatty liver disease drug maker Pharmaxis adds pancreatic cancer to lineup
Reply Retweet Like
Pharmaxis retweeted
Proactive Investors Feb 21
Pharmaxis begins phase one clinical trial of compound targeting pancreatic cancer via
Reply Retweet Like
Pharmaxis Feb 21
Pleased to announce the launch of our Phase 1 clinical trial which is taking a new approach to tackling pancreatic cancer.
Reply Retweet Like
Pharmaxis Jan 30
Pharmaxis well funded as potential partners assess its anti‐fibrotic mechanisms via
Reply Retweet Like
Pharmaxis Jan 29
Key developments outlined in the Quarterly Report including our leading position in NASH clinical research, next program to start phase 1 and reimbursement for Bronchitol in Russia.
Reply Retweet Like
Pharmaxis Jan 17
Great to see ’ leading research in NASH highlighted.
Reply Retweet Like
Pharmaxis retweeted
KALKINE Jan 17
The company believes that its inhibitor program is now ready to enter phase 2 clinical studies. Following this news, the share price of the company increased by 8 percent on ASX as on 17 January 2019.
Reply Retweet Like
Pharmaxis retweeted
AusBiotech Jan 17
Pharmaxis updates on LOXL2 studies
Reply Retweet Like
Pharmaxis retweeted
Proactive Investors Jan 16
Pharmaxis LOXL2 program phase 2 ready after completion of 13-week toxicity studies via
Reply Retweet Like
Pharmaxis Dec 19
announces New Drug Application for Bronchitol in USA
Reply Retweet Like
Pharmaxis Dec 12
Pharmaxis reveals first sales of Aridol® in US following successful relaunch via
Reply Retweet Like
Pharmaxis Dec 12
An asthma diagnostic developed by notches up first distributor sales in the USA.
Reply Retweet Like
Pharmaxis retweeted
Proactive Investors Nov 22
Pharmaxis advancing partnership talks for LOXL2, and increasing anti fibrotic applications via
Reply Retweet Like
Pharmaxis Nov 21
Chairman Malcolm McComas details the successful evolution of the company’s amine oxidase chemistry platform at the AGM
Reply Retweet Like
Pharmaxis Nov 20
Plenty of positive feedback from our research day presentations and lab tours. You can catch up here:
Reply Retweet Like
Pharmaxis Nov 19
Pharmaxis moving into phase I clinical trial of its small molecule LOX inhibitor via
Reply Retweet Like
Pharmaxis Nov 19
Catch up on the Investor Briefing Day by seeing vidoes of all the presentations on our website
Reply Retweet Like
Pharmaxis Nov 19
How an antifibrotic could help treat . The Garvan Institute's Thomas R Cox presents on the collaboration with Pharmaxis.
Reply Retweet Like